Enterprise Value
31.72M
Cash
38.54M
Avg Qtr Burn
-16.06M
Short % of Float
11.19%
Insider Ownership
4.11%
Institutional Own.
44.43%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATRC-101 (monoclonal antibody) Details Solid tumor/s | Failed Discontinued |